Latest News and Press Releases
Want to stay updated on the latest news?
-
COMMUNIQUE DE PRESSE BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024 En utilisant une...
-
PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee...
-
Dublin, Dec. 28, 2023 (GLOBE NEWSWIRE) -- The "Viscosupplementation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application,...
-
Dublin, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The "Orthopedic Regenerative Surgical Products Market Size, Share & Trends Analysis Report By Product (Allografts, Viscosupplements), By End-use...
-
Dublin, Feb. 27, 2023 (GLOBE NEWSWIRE) -- The "Global Viscosupplementation Market, By Product Type, By End User, Estimation & Forecast, 2017-2030" report has been added to ...
-
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Orthopedic Regenerative Surgical Products Market Size, Share & Trends Analysis Report by Product (Allograft, Synthetic, Cell-based,...
-
INFORMATION RÉGLEMENTÉE Aucune différence statistiquement significative n’a été observée dans la réduction de la douleur du genou entre JTA-004, le placebo et le comparateur actif 3 mois après le...
-
REGULATED INFORMATION No statistically significant difference in knee pain reduction between JTA-004, placebo and active comparator, 3 months after treatment; favorable JTA-004 safety profile...
-
INFORMATION RÉGLEMENTÉE Les premiers résultats de la phase III évaluant JTA-004 sont prévus pour la première moitié de septembre La phase IIb évaluant ALLOB est en cours malgré un...
-
REGULATED INFORMATION JTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow due to COVID-19 pandemic Gosselies,...